Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

Video

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, US oncology medical director of Gynecologic Oncology Research and a professor at the University of Arizona College of Medicine, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Since its approval in 2014, the triplet regimen of bevacizumab (Avastin), paclitaxel, and cisplatin/topotecan has remained the standard frontline therapy for these patients, Monk explains. The combination, which contains the first targeted therapy approved in a gynecologic malignancy, is associated with an overall survival benefit for patients with metastatic disease.

Additionally, in June 2018, pembrolizumab (Keytruda) received regulatory approval for the treatment of women with metastatic cervical cancer who experience disease progression on or after chemotherapy and whose tumors express PD-L1 with a combined positive score of 1 or more. However, the response rate was only 14.3%, says Monk.

Metastatic or recurrent cervical cancer remains a lethal disease. As such, novel regimens are needed to improve responses for patients with this malignancy, concludes Monk.

Related Videos
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Julia Foldi, MD, PhD
Carmen Guerra, MD, MSCE, FACP